{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:39:10Z","timestamp":1792784350420,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Piramal Enterprises Limited"}],"content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.lungcan.2013.08.010","type":"journal-article","created":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T02:16:28Z","timestamp":1378174588000},"page":"214-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines"],"prefix":"10.1016","volume":"82","author":[{"given":"Nitesh","family":"Shirsath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Rathos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sivaramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2013.08.010_bib0005","series-title":"Cancer Facts and Figures 2012","first-page":"1","author":"American Cancer Society","year":"2012"},{"issue":"5","key":"10.1016\/j.lungcan.2013.08.010_bib0010","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.200504-531OE","article-title":"One hundred years of lung cancer","volume":"172","author":"Spiro","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.lungcan.2013.08.010_bib0015","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1164\/rccm.200202-070SO","article-title":"Lung cancer \u2013 where are we today? Current advances in staging and nonsurgical treatment","volume":"166","author":"Spiro","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"12 Pt 2","key":"10.1016\/j.lungcan.2013.08.010_bib0020","doi-asserted-by":"crossref","first-page":"4210s","DOI":"10.1158\/1078-0432.CCR-040009","article-title":"Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms","volume":"10","author":"Socinski","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.lungcan.2013.08.010_bib0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.beha.2008.08.003","article-title":"Is the focus moving toward a combination of targeted drugs?","volume":"21","author":"Grant","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"13","key":"10.1016\/j.lungcan.2013.08.010_bib0030","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","article-title":"The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2","volume":"22","author":"Kramer","year":"2003","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.lungcan.2013.08.010_bib0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/13543784.13.1.21","article-title":"Histone deacetylase inhibitors in clinical development","volume":"13","author":"Rosato","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2013.08.010_bib0040","first-page":"S91","article-title":"Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases","volume":"83","author":"Gotticher","year":"2004","journal-title":"Ann Hematol"},{"issue":"24","key":"10.1016\/j.lungcan.2013.08.010_bib0045","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"Gotticher","year":"2001","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.lungcan.2013.08.010_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1368-7646(02)00141-3","article-title":"The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy","volume":"6","author":"Grant","year":"2003","journal-title":"Drug Resist Updat"},{"issue":"2\u20133","key":"10.1016\/j.lungcan.2013.08.010_bib0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0163-7258(02)00182-1","article-title":"Structure-based design of cyclin-dependent kinase inhibitors","volume":"93","author":"Davies","year":"2002","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.lungcan.2013.08.010_bib0060","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1054\/drup.2000.0165","article-title":"The relevance of drug sequence in combination chemotherapy","volume":"3","author":"Shah","year":"2000","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.lungcan.2013.08.010_bib0065","first-page":"73","article-title":"Cell cycle control and cancer","volume":"96","author":"Sherr","year":"2001","journal-title":"Harvey Lect"},{"issue":"3","key":"10.1016\/j.lungcan.2013.08.010_bib0070","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/1535-7163.MCT-06-0613","article-title":"In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00","volume":"6","author":"Joshi","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.lungcan.2013.08.010_bib0075","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/1535-7163.MCT-06-0614","article-title":"P276-00 a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models","volume":"6","author":"Joshi","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.lungcan.2013.08.010_bib0080","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-11-77","article-title":"P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in both in vitro and in vivo mantle cell lymphoma cell lines","author":"Shirsath","year":"2012","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2013.08.010_bib0085","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.leukres.2010.12.010","article-title":"Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1and RNA polymerase II-dependent transcription","volume":"35","author":"Manohar","year":"2011","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.lungcan.2013.08.010_bib0090","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00001813-199508000-00005","article-title":"Development of a propidium fluorescence assay for proliferation and cytotoxicity assays","volume":"6","author":"Dengler","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2013.08.010_bib0095","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-161","article-title":"Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers","author":"Rathos","year":"2012","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.lungcan.2013.08.010_bib0100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.lungcan.2013.08.010_bib0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2407-13-29","article-title":"Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cells","volume":"13","author":"Rathos","year":"2013","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2013.08.010_bib0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF00051376","article-title":"Human tumor cloning assays: application in clinical oncology and new antineoplastic agent development","volume":"7","author":"Von Hoff","year":"1988","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"10.1016\/j.lungcan.2013.08.010_bib0115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3181\/00379727-213-44046","article-title":"p21, a negative regulator of the cell cycle","volume":"213","author":"Gartel","year":"1996","journal-title":"Proc Soc Exp Biol Med"},{"issue":"1","key":"10.1016\/j.lungcan.2013.08.010_bib0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0092-8674(94)90573-8","article-title":"p27, a novel inhibitor of G1 cyclin- CDK protein kinase activity, is related to p21","volume":"78","author":"Toyoshima","year":"1994","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.lungcan.2013.08.010_bib0125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/mol.65.3.520","article-title":"Valproic acid inhibits angiogenesis in vitro and in vivo","volume":"65","author":"Michaelis","year":"2004","journal-title":"Mol Pharmaol"},{"issue":"28","key":"10.1016\/j.lungcan.2013.08.010_bib0130","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1038\/sj.onc.1209417","article-title":"Modulation of cellular radiation responses by histone deacetylase inhibitors","volume":"25","author":"Karagiannis","year":"2006","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.lungcan.2013.08.010_bib0135","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.lungcan.2013.08.010_bib0140","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.lungcan.2013.08.010_bib0145","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1535-7163.MCT-05-0184","article-title":"Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC","volume":"4","author":"Li","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.lungcan.2013.08.010_bib0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1479-5876-11-42","article-title":"Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma","volume":"11","author":"Mishra","year":"2013","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.lungcan.2013.08.010_bib0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2008.11.005","article-title":"Growth inhibition in antimycin A treated-lung cancer Calu-6 cells via inducing a G1 phase arrest and apoptosis","volume":"65","author":"Han","year":"2009","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213003656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213003656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T08:55:24Z","timestamp":1539420924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500213003656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0169500213003656"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.08.010","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}